15 Amendments of Anja HAZEKAMP related to 2019/2816(RSP)
Amendment 36 #
Recital B
B. whereas the wide use of pharmaceuticals in human and veterinary medicines, including antimicrobial agents, has increased their concentrations in many environmental reservoirs such as soils, sediments and waterbodies in the past 20 years; whereas environmental concentrations are likely to increase as the population ages and grows, and climate change will worsen the pollution of water by pharmaceutical residues as at times of drought concentrations will be higher; whereas the largest source of pharmaceuticals entering the environment is their use and disposal;
Amendment 44 #
Recital D
D. whereas the excessive and incorrect use of antibiotics, particularly in livestock farming, and more generally poor practices in both human and veterinary medicine, have progressively rendered antimicrobial resistance a massive threat to human and animal health; whereas intensive livestock farming, where large numbers of animals are kept in close proximity to each other, leads to the excessive use of veterinary medicines including antibiotics;
Amendment 82 #
Paragraph 4
4. Recalls that any future initiatives in the field of the environmental impact of pharmaceuticals should be science andbased on the precautionary principle, target driven, as well asnd technology neutral, making sure that safety and efficacy still remain key priority features for access for patients to pharmaceutical treatments;
Amendment 88 #
Paragraph 5
5. Considers that a holistic approach is needed to tackle pharmaceutical pollution at source, taking into account the entire life cycle of drugs; stresses that regulatory actions have to be taken in line with the precautionary principle and the control at source principle; highlights that the polluter pays principle should apply, primarily covering the manufacturing process, but also incentivising better prescription practices and consumer behaviourentire lifecycle of pharmaceuticals from the manufacturing process to prescription, and from use to disposal and waste treatment;
Amendment 119 #
Paragraph 10
10. Asks for a special focus to be put on emission hot spots, such as hospitals and, pharmaceutical production plants and intensive stockbreeding areas;
Amendment 125 #
Paragraph 10 a (new)
10 a. Calls on the Commission to develop Extended Producer Responsibility (EPR) schemes, in order to finance depollution measures in line with the polluter pays principle;
Amendment 142 #
Paragraph 13
13. Calls on the Member States and on the Commission to promote awareness- raising campaigns among veterinaries and physicians on the prudent use of pharmaceuticals, particularly of antimicrobials; calls on actors in the pharmaceutical supply chain to contribute to providing to patients and stockbreeders with sufficient information on how incorrectly disposed medicines may negatively impact the environment; calls for on-pack labelling in the form of an appropriate pictogramme to inform consumers how to properly dispose of unused medicines;
Amendment 160 #
Paragraph 16
16. Considers that the environmental impacts of pharmaceuticals cnew and existing pharmaceutical substances pharmaceuticals should be included into the benefit-risk assessment of human medicines, as is already the case for veterinary medicines; emphasises that metabolites, degradation products and cocktail effects of pharmaceutical substances should also be considered therein;
Amendment 198 #
Paragraph 26
26. Stresses that measures must be based on scientific evidencthe precautionary principle and calls on all relevant players to ensure that actions taken do not jeopardise access to safe and effective pharmaceutical treatments for human patients and animals; in this regard, supports the Commission’s intention to reduce waste by allowing that medicines be dispensed in quantities better matching needs, including by optimising the package size, and to explore the possibility to extend expiry dates for medicines to avoid that medicines that can still be safely used are unnecessarily thrown away;
Amendment 201 #
Paragraph 27
27. Considers that the overall per capita drug consumption should be reduced, without jeopardising patients’ health; is of the opinion that the number of animals on stock farms and the overall per animal veterinary medicines consumption should also decrease and that intensive stockbreeding should be run down;
Amendment 219 #
Paragraph 30
30. Calls for full enforcement of the existing provisions with regard to take- back schemes for unused medicines and calls on Member States which have not yet set up these provisions to do so;
Amendment 238 #
Paragraph 33
33. Calls on the Commission to address the possible impact of pharmaceuticals on the watchlist pursuant to the Water Framework Directive and to assess whether the list should be updated; calls on the Commission to propose a soil framework directive, focusing in particular on the concentration of antibiotics in the soil;
Amendment 242 #
Paragraph 34
34. Highlights that comprehensive monitoring of antibiotics has been developed in farming; calls on the Commission to also develop a monitoring system in relation to human antibiotics; calls on the Commission to propose a pharmaceuticals monitoring programme, focusing in particular on the concentration of antibiotics in the soil;
Amendment 246 #
Paragraph 35
35. Emphasises the need to support further research, particularly under the next multi-annual financial framework, on the direct impact on human health and ecology of exposure to pharmaceuticals and their residues in the environment and on better understanding how pharmaceuticals enter and persist in the environment;
Amendment 255 #
Paragraph 37
37. Recalls that pharmaceutical environmental information such as the impact on water, environmental behaviour, degradability and possible cocktail effects plays a key role for risk management and that this type of information should be transparent and made available to relevant stakeholders;